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Summary
Factors controlling the onset and progression of ex-
tracellular amyloid diseases remain largely unknown.
Central to disease etiology is the efficiency of the en-
doplasmic reticulum (ER) machinery that targets de-
stabilized mutant proteins for degradation and the
enhanced tendency of these variants to aggregate if
secreted. We demonstrate that mammalian cells se-
crete numerous transthyretin (TTR) disease-associ-
ated variants with wild-type efficiency in spite of com-
promised folding energetics. Only the most highly
destabilized TTR variants are subjected to ER-associ-
ated degradation (ERAD) and then only in certain tis-
sues, providing insight into tissue selective amy-
loidosis. Rather than a “quality control” standard
based on wild-type stability, we find that ER-assisted
folding (ERAF), based on global protein energetics,
determines the extent of export. We propose that
ERAF (influenced by the energetics of the protein
fold, chaperone enzyme distributions, and metabolite
chaperones) in competition with ERAD defines the
unique secretory aptitude of each tissue.
Introduction
Proteins susceptible to extracellular misfolding and
amyloidogenesis, leading to human disease through a
gain of toxic function mechanism, are secreted from
the cell. This raises the possibility that the intracellular
folding, secretion, and degradation pathways could in-
fluence the age of onset, severity, and tissue specificity
of familial amyloidoses (Cohen and Kelly, 2003; Kelly,
1996). Folding within the secretory pathway of mamma-
lian cells is initiated in the endoplasmic reticulum (ER).
Here, folding efficiency is challenging, owing to the high
protein concentrations and physiologic temperature,
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versity, 581 83 Linkoping, Sweden.ing, such as the disulfide isomerases. A mutation in a
secreted protein can lead to decreased folding effi-
ciency within the ER and reduced export (Gelman and
Kopito, 2003; Fan, 2003). Misfolded or misassembled
proteins are retained in the ER by chaperone binding,
dislocated to the cytoplasm and degraded by the pro-
teasome, a process referred to as ER-associated deg-
radation (ERAD; Wickner et al., 1999; Mori, 2000; Ell-
gaard et al., 1999).
A current view of ER export is that only proteins that
have attained their native structure in the ER are ex-
ported efficiently through selection by the COPII bud-
ding machinery (Lee et al., 2004; LaPointe et al., 2004;
Wickner et al., 1999; Mori, 2000; Ellgaard et al., 1999).
While it is accepted that proper folding and quaternary
structural acquisition is necessary for secretion and
that secretion efficiency correlates with thermodynamic
stability, the primary literature on which these concepts
are based is limited. Studies using mammalian proteins
with 3 or 4 disulfide bonds, many expressed in yeast,
and soluble variants of transmembrane proteins includ-
ing the T cell receptor, yielded the concept that thermo-
dynamic stability predicts secretion efficiency (Kowal-
ski et al., 1998a; Kowalski et al., 1998b; Shusta et al.,
1999; Omura et al., 1991). Studies on hemagluttinin and
soluble heavy chains lacking their complementary light
chain led to the notion that proteins must attain their
native quaternary structures prior to secretion (Bole et
al., 1986; Copeland et al., 1986). Exceptions to the
general rules that thermodynamic stability predicts
secretion efficiency and that native quaternary struc-
tural acquisition must precede secretion are known to
exist (Taniyama et al., 1992; Musil and Goodenough,
1993) and combined with the paucity of data on the
secretion of native soluble proteins, call into question
the generality of these accepted relationships.
The extracellular misfolding and misassembly of the
protein transthyretin (TTR) into a variety of aggregates,
including amyloid fibrils, is linked to numerous neuro-
degenerative diseases and cardiomyopathies. TTR is a
soluble nonglycosylated protein that is secreted into
the blood and the cerebrospinal fluid (CSF) as a func-
tional native tetramer that transports both thyroxine (T4)
and holo-retinol binding protein, using orthogonal sites
(Hamilton and Benson, 2001). TTR amyloidogenesis oc-
curs by rate-limiting tetramer dissociation, followed by
partial monomer unfolding rendering TTR misassembly
competent (Colon and Kelly, 1992; Hammarstrom et al.,
2002; Lai et al., 1996). Wild-type TTR deposition leading
to sporadic amyloid disease occurs in as much as 10%
of the population over 80 years of age (Westermark et
al., 1990). Familial amyloidoses, associated with one of
over 100 TTR mutations typically present earlier, are
often more severe, with several variants exhibiting tis-
sue-selective deposition and pathology (Hammarstrom
et al., 2003a; Sekijima et al., 2003; Plante-Bordeneuve
et al., 1998; Jacobson et al., 1992). Familial TTR amy-
loid diseases include the systemic neuropathies (famil-
ial amyloid polyneuropathy [FAP]), cardiomyopathies
(familial amyloid cardiomyopathy [FAC]), and central
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74nervous system amyloidoses (CNSA; Benson, 1996; p
sIkeda, 2002). The typical FAP, FAC, and CNSA patients
are heterozygotes, hence their tetramers are made up a
lof a near-statistical distribution of mutant and wild-type
subunits, although variant TTR typically deposits selec- i
ptively, likely because tetramers rich in variant subunits
are less stable and are more easily dissociated and o
ptransformed into amyloid (Dwulet and Benson, 1983;
Dwulet and Benson, 1984; Wallace et al., 1986). a
sA previous energetic characterization of a few FAP/
FAC variants led us to speculate that both the kinetic c
pstability of the tetramer, defined by the rate of tetramer
dissociation, and the thermodynamic stability of the b
ttetrameric fold, defined by the linked tetramer-folded
monomer-unfolded monomer transition, considered to- p
egether may predict disease severity (Hammarstrom et
al., 2002). However, we recently reported variants that t
tare highly unstable yet do not exhibit severe systemic
pathology (Hammarstrom et al., 2003a; Sekijima et al., b
2003). Curiously, these TTR variants exhibit a late onset
CNS-selective pathology and are present at very low R
concentration in the blood, suggesting secretion defici-
encies by the liver that are not manifested in the cho- H
roid plexus, the site of TTR synthesis in the CNS (Ham- A
marstrom et al., 2003a; Sekijima et al., 2003). Thus, T
cell-specific secretion efficiency differences could be t
an important parameter in the tissue specificity of hu- 1
man amyloidosis, as these control TTR concentration (
which strongly influences the rate of TTR fibril forma- e
tion (Hurshman et al., 2004; Sekijima et al., 2003). In- T
deed, treatment of V30M FAP by liver transplantation c
decreases the V30M serum concentration by 95%, a
demonstrating that reducing the concentration of vari- a
ant TTR is sufficient to prevent further deposition of p
amyloid in most tissues, ameliorating disease (Holm- i
gren et al., 1993; Suhr et al., 2002; Ando et al., 1995). i
qWhile highly destabilized mutant proteins are nor-
mally subjected to ERAD, they can be secreted at
thigher levels when small molecules bind to and stabi-
lize the native state in the ER allowing export, avoiding m
aproteasomal degradation. T4 binding to TTR could sta-
bilize energetically compromised variants in this fash- c
1ion, increasing secretion efficiency, especially in tissues
like the choroid plexus that are rich in T4 and lack com- p
lpetitive T4 binding proteins (Dickson et al., 1987). While
the liver is also rich in T4, there are numerous proteins p
sthat bind T4 in this tissue, one with higher affinity than
TTR; hence, the T4 available to stabilize TTR for export 2
tis limited. Exogenous small molecules that increase the
natural level of secretion, known as pharmacological 1
pchaperones, are well established in the literature and
have the potential to improve loss-of-function diseases t
tprovided the mutant proteins are stable in their destina-
tion environment in the absence of the bound small M
hmolecules (Fan, 2003; Sawkar et al., 2002; Bernier et
al., 2004). p
sHerein, we investigate the energetics and secretion
efficiency of wild-type TTR and 32 variants, 23 of which a
tare disease associated, using biophysical and secre-
tion assays to provide insight into why different TTR a
rvariants exhibit tissue-selective pathology. TTR secre-
tion efficiency does not correlate very well with either a
2thermodynamic or kinetic stability; however, consider-
ation of both kinetic and thermodynamic stability nicely tredicts TTR secretion efficiency. ERAD leads to low
ecretion for only the most highly destabilized TTR vari-
nts, thus preventing severe early onset systemic amy-
oidosis by keeping the concentration of these variants
n the serum low. Tissue-specific secretion differences,
ossibly mediated by T4 chaperoning, allow secretion
f highly destabilized TTR variants from the choroid
lexus, but not the liver, allowing these variants to initi-
te CNS-selective amyloidosis. Analysis of the relation-
hip between folding energetics and secretion effi-
iency reveals that even substantially destabilized
roteins can be secreted. Rather than export being
ased on a “quality control” standard relative to wild-
ype stability, we now show that export by ER-assisted
rotein folding (ERAF) is an error-prone process influ-
nced by numerous factors which determine the frac-
ion of protein destined for export versus degradation;
hus, some tissues are more permissive for secretion
ased on their unique physiology.
esults
ighly Destabilized TTR Variants
re Not Secreted Efficiently
o determine the secretion rate of TTR variants, we
ransfected baby hamster kidney (BHK) cells (Figures
A–1C) and met murine hepatocytes (MMH) cells
Spagnoli et al., 1998; Figures 1D–1F), neither of which
xpress endogenous TTR, with wild-type TTR and/or
TR disease-associated variants using a transient vac-
inia expression system (Tisdale et al., 1992; Wang et
l., 2004; see Table S1 in the Supplemental Data avail-
ble with this article online). Transfected cells were
ulse labeled with [35S]-methionine and chased for the
ndicated time. Intracellular and extracellular TTR was
mmunoprecipitated, and the amount of protein was
uantified by SDS-PAGE.
BHK cells began secreting wild-type TTR 30 min after
he pulse label (Figures 1A and 1B). Surprisingly, the
ost pathogenic systemic variant (L55P; Jacobson et
l., 1992) was secreted with similar kinetics and effi-
iency as wild-type TTR in both cell lines (Figures 1A–
F). In contrast, the amount of secreted A25T, as com-
ared to wild-type, was markedly reduced in both cell
ines (Figures 1C and 1F), consistent with the low-
lasma A25T TTR concentration in individuals pre-
enting with A25T CNS amyloidosis (Sekijima et al.,
003). Similarly, secretion of D18G TTR was barely de-
ectable from either BHK cells or MMH cells (Figures
A–1F), consistent with the undetectable levels of
lasma D18G TTR in CNS patients harboring this muta-
ion (Hammarstrom et al., 2003a). Professional secre-
ory cells such as hepatic cells (represented by the
MH cell line; Spagnoli et al., 1998; Figures 1D–1F) ex-
ibit higher overall TTR secretion efficiency as com-
ared to BHK cells (Figures 1B and 1E, note the y axis
cale change). However, a comparison of the absolute
mount of secreted variant TTR from MMH cells relative
o wild-type TTR at 90 min reveals that A25T and D18G
re secreted at significantly lower levels, 33% and 5%,
espectively (Figure 1F). A25T and especially D18G TTR
re highly destabilized variants (Hammarstrom et al.,
003a; Sekijima et al., 2003), possibly explaining why
hey fail to be secreted efficiently.
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75Figure 1. Efficiency and Kinetics of TTR Secretion
The extent of TTR secretion was evaluated by transfecting BHK and MMH cells with wild-type, disease-associated variants, and monomeric
TTR variants using a transient vaccinia expression system (see Experimental Procedures).
(A) Autoradiogram of immunoprecipitated intracellular and extracellular [35S]-Met pulse-labeled TTR from BHK cells as a function of chase
time. The arrowhead indicates the 15 kDa TTR SDS-PAGE gel band.
(B) Quantification of intracellular and secreted TTR by densitometric scanning of the autoradiogram in (A); wild-type (open circles), L55P
(filled circles), A25T (filled squares), D18G (open triangles). Secretion efficiency (%) = 100* ([secreted TTR at given time t]/[intracellular TTR +
secreted TTR at t = 30 min]).
(C) Amount of secreted TTR variant relative to wild-type (100%) as a function of time from BHK cells. In these cases, the relative secretion
was calculated by the following equation: relative secretion = (secreted variant TTR at time t)/(secreted wild-type TTR at time t), demonstrating
that much less total protein is secreted from A25T- and D18G-producing cells.
(D–F) Extent of TTR secretion in MMH cells. Conditions in (D)–(F) identical to those described for (A)–(C), respectively.ERAD Directs Degradation of Poorly
Secreted TTR Variants
The intracellular distribution of wild-type and D18G TTR
was examined using indirect immunofluorescence mi-croscopy in BHK cells (Figure 2A). Both wild-type and
D18G TTR are present in the ER, as revealed by overlap
with the ER marker protein calnexin (Figure 2A, top two
rows). Wild-type TTR was also found in a punctate dis-
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c(A) Distribution of wild-type and D18G TTR in BHK cells using indi-
crect immunofluoresence. The left column shows distribution of TTR
ivisualized with a goat polyclonal antibody conjugated to rhoda-
mine. The middle column (red images) shows the distribution of ER b
and Golgi markers calnexin (CNX) and α-1,2-mannosidase II e
(ManII), respectively, visualized with anti-mouse or anti-rabbit anti- t
bodies, respectively, conjugated to fluorescein. The right column
mdisplays the merged images. TTR overlap with organelle markers
is depicted in yellow.
(B) Densitometric quantification of intracellular and secreted TTR A
from BHK cells, transiently transfected with Lipofectamine Plus, in T
the presence and absence of proteasome inhibitors. ERAD (%) = W
100 (1 − [intracellular TTR + secreted TTR at given time t])/([intracel- h
lular TTR + secreted TTR at t = 0 hr]). Wild-type TTR with vehicle/
wDMSO (open circles), D18G with vehicle/DMSO (filled circles),
sD18G treated with 30 M MG132 (filled triangles), D18G treated
with 5 M epoxomycin (filled diamonds), D18G treated with 10 M i
lactacystin (filled squares). u
pribution pattern that overlapped with the Golgi marker
-1,2,-mannosidase II (Figure 2A, third row), suggesting
hat it is efficiently trafficked through the normal protein
ecretory pathway. In contrast, D18G TTR exhibited
inimal overlap with the α-1,2,-mannosidase II (Figure
A, bottom row), suggesting inefficient ER export of
his TTR variant. We conclude that D18G TTR is largely
estricted to the ER, consistent with its inefficient
ecretion (Figure 1).
The substantially reduced secretion of D18G TTR
rom both BHK and MMH cell lines and its retention
ithin the ER suggests that D18G may be targeted for
R-associated degradation (ERAD). Pulse-chase ex-
eriments were performed in the presence and ab-
ence of proteasome inhibitors to test this possibility
Figure 2B). Both intracellular and secreted TTR were
uantified by SDS-PAGE as described above to deter-
ine the extent of intracellular TTR degradation relative
o the quantity of TTR synthesized. In the absence of
roteasome inhibitors, 74% of the labeled D18G TTR
as degraded by the 6 hr time point (Figure 2B). In con-
rast, the addition of proteasome inhibitors reduced the
egradation of D18G TTR to <50% (Figure 2B). The in-
ibitors had no effect on the recovery of wild-type TTR
data not shown), suggesting that the properly folded
ild-type protein is not targeted for degradation by
RAD. These results indicate that the proteasome con-
ributes to the degradation of highly destabilized TTR
utants.
etramerization Is Not Required for Efficient
TR Secretion
18G TTR is largely monomeric as a result of its highly
estabilized tetrameric structure, the monomer being
nstable and adopting multiple conformations. The in-
bility of D18G TTR to tetramerize raises the possibility
hat tetramerization of TTR is required for efficient
ecretion. To investigate whether a normally folded TTR
onomer could be secreted, we utilized the previously
eported F87M/L110M TTR variant that exists as a sta-
ly folded monomer (M-TTR) at concentrations%2 mg/
l (Jiang et al., 2001). M-TTR was secreted at 70% of
he efficiency of wild-type TTR in BHK cells (Figure 3),
ubstantially higher than A25T (unstable tetramer) and
18G (conformationally heterogeneous monomer) TTR.
hus, TTR can be secreted as a monomer. While we
annot rule out the possibility that the luminal ER con-
entration of TTR exceeds 2 mg/ml, transiently result-
ng in M-TTR tetramerization, this seems highly unlikely
ased on the low levels of expression. A more likely
xplanation for the very poor secretion of D18G TTR is
hat this variant cannot form a normally folded mono-
eric β sheet structure (Hammarstrom et al., 2003a).
Global Energetic Analysis of Disease-Associated
TR Variants
e set out to understand whether protein energetics
ad the potential to predict the secretion efficiency of
ild-type TTR and TTR variants. The thermodynamic
tability of 23 disease-associated TTR variants, includ-
ng D18G and A25T TTR, were evaluated by comparing
rea denaturation midpoints (Cm), which directly re-
orts on the linked tetramer 4 folded monomer and
Secretion Efficiency Influences Amyloidosis
77Figure 3. Secretion Efficiency of Monomeric (F87M/L110M) TTR
(M-TTR)
Secretion efficiency (defined in Figure 1) of M-TTR (open squares)
from BHK cells determined by densitometric scanning of the auto-
radiogram in the inset. Wild-type TTR data (open circles) is in-
cluded to enable a comparison.folded monomer4 unfolded monomer equilibria (Fig-
ure 4, x axis; Hammarstrom et al., 2002). All of the famil-
ial disease-associated TTR variants are thermodynami-
cally less stable than wild-type TTR (Cm = 3.4; Figure
4). TTR variants predominantly associated with CNS
deposition (L12P, D18G, A25T, V30G, A36P, G53E, F64S,
and Y69H) exhibited the lowest thermodynamic sta-
bility (Cm < 2) characterized to date. The other disease
associated TTR variants (Cm R 2) typically exhibit sys-
temic (non-CNS) neuropathy and/or cardiomyopathy
(Figure 4).
The kinetic stability, defined by the rate of tetramer
dissociation, also has the potential to influence secre-
tion efficiency. While the pathogenic mutations were all
less stable than wild-type TTR, the kinetic stability var-
ied substantially (Figure 4, y axis). The dissociation rate
was quantified by linking the slow tetramer dissociation
rate to the much faster process of monomer unfolding,
easily monitored by fluorescence (Hammarstrom et al., and Figure S1). The three-dimensional fit of secretion
Figure 4. Relationship between Thermody-
namic (x Axis; Cm of Urea-Mediated Dissoci-
ation/Denaturation Curve) and Kinetic Sta-
bility (y Axis, t1/2 of Tetramer Dissociation/
Unfolding) Evaluated In Vitro
Indicated is the disease phenotype of TTR
variants including suppressor mutations (black
circles), nonpathogenic mutations (white cir-
cles), CNS-prominent mutations (blue dia-
monds), non-CNS prominent mutations (red
diamonds), and non-CNS prominent muta-
tions that sometimes exhibit CNS symptoms
(green diamonds).2002). This rate of tetramer dissociation was measured
at five urea concentrations, all high enough to render
the monomer unfolding process irreversible, allowing
extrapolation of the dissociation rate to 0 M urea. A
number of TTR variants dissociated faster than wild-
type TTR, while others displayed much slower kinetics
(Figure 4). In contrast to the pathology-related distribu-
tion of thermodynamic stability, the kinetic stability of
the pathological variants displayed no qualitative trend.
Even the CNS variants displayed a wide range of disso-
ciation rates, from very rapid (A25T) to very slow (Y69H
and F64S). Because D18G is monomeric, the reported
rate for this variant is the unfolding rate, which is sub-
stantially faster than the reported tetramer dissoci-
ation rates.
Secretion Efficiency Is Best Predicted When Kinetic
and Thermodynamic Stability Are Considered
Together Utilizing a Combined Stability Score
In order to determine the relationship between protein
energetics and cellular secretion, we compared the
secretion efficiency and protein stability of 32 TTR vari-
ants (23 naturally occurring variants and 9 created by
introducing disease-associated mutations onto the
M-TTR background [F87M/L110M] to generate mono-
mers). Surprisingly, the secretion efficiency of the TTR
variants did not strongly correlate with either kinetic
stability (Figure 5A, R2 = 0.49) or thermodynamic sta-
bility (Figure 5B, R2 = 0.22) as previously described (Ko-
walski et al., 1998a; Kowalski et al., 1998b; Shusta et
al., 1999; Omura et al., 1991). However, it seemed rea-
sonable that secretion efficiency might depend on
some combination of thermodynamic and kinetic sta-
bility because these energetic parameters together
should dictate the steady-state population of both
folded TTR subject to export and the misfolded popula-
tion subject to ERAD. In order to evaluate this possi-
bility, a three-dimensional scatter plot was prepared
with kinetic and thermodynamic stability as the inde-
pendent variables and secretion efficiency as the de-
pendent variable. This scatter plot was subjected to a
linear regression in two dimensions, fitting these data
to a plane representative of the overall combined sta-
bility of the protein variants (Supplemental Discussion
Cell
78Figure 5. Relationship between Protein Energetics and Secretion Efficiency
(A) Relationship between relative secretion efficiency (defined in Figure 1; wild-type = 100%) and the t1/2 of dissociation/unfolding (extrapo-
lated to 0 M urea). Open symbols indicate variants introduced into the M-TTR (F87M/L110M) background. Closed symbols indicate all the
naturally occurring human TTR mutations. Red line is a linear fit with an R2 = 0.49 (Table S2).
(B) Relationship between relative secretion efficiency and thermodynamic stability as reflected by the midpoint (Cm) of urea denaturation
curve. Symbols as in (A). Red line is a linear fit with an R2 = 0.22 (Table S2).
(C) Relationship between relative secretion efficiency and the combined stability score calculated from a three-dimensional fitting analysis
(Figure S1 and see Supplemental Discussion). Secretion efficiency and the combined stability score correlate up to a threshold value (dotted
line) beyond which all variants are secreted with wild-type efficiency.
(D) Relationship between disease phenotype and combined stability score (normalized to wild-type = 1). Suppressor mutations (black bars);
wild-type and mutations displaying wild-type-like pathology (gray bars); pathogenic mutations (white bars); variants exhibiting a notable CNS-
selective phenotype (hatched bars). The most destabilized TTR variants are detected by ERAD.efficiency as a function of both thermodynamic and ki- e
dnetic stability exhibits a strikingly improved correlation
(Figure S1, R2 = 0.69). Using the weighting parameters t
ddetermined from the three-dimensional linear fit (Figure
S1), a combined stability score was calculated for each c
mvariant, encompassing both thermodynamic and ki-
netic protein stability, by inserting the experimentally t
cderived values for protein stability into the equation de-
fining the fit of the three-dimensional plot (Supplemen- a
Ttal Discussion). Using the combined stability score, the
three-dimensional plot was compressed into a two- c
ndimensional figure with secretion efficiency on the y
axis and the combined stability score on the x axis (Fig- t
dure 5C). The improved correlation when both kinetic
and thermodynamic stability of the TTR tetramer are d
(considered strongly suggests that ER-assisted foldingnabling secretion detects a combination of thermo-
ynamic and kinetic stability. This reflects the expecta-
ion that both kinetic and thermodynamic parameters
ictate the near-native population within the ER that is
apable of interacting with the COPII cargo selection
achinery. From these results, it is now apparent that
he ERAD machinery detects TTR variants having a
ombined stability score of <0.8, above which variants
re secreted at maximal efficiency (Figures 5C and 5D).
hus, ERAD substantially reduces the extracellular con-
entration of only the most destabilized variants, but
ot variants above this threshold, like L55P. ERAD
argeting of the most unstable variants explains why
iseases associated with these TTR variants are not as
evastating as protein energetics alone might predict
Hammarstrom et al., 2002). L55P exhibits a devasta-
Secretion Efficiency Influences Amyloidosis
79ting early onset FAP phenotype because it is the variant
most prone to extracellular amyloidogenesis that can
be secreted at near-wild-type levels.
Stabilization of the Tetrameric Structure by T4
and Other Native State Stabilizers Increases
the Secretion Efficiency of Highly
Destabilized TTR Variants in BHK Cells
To investigate the possibility that T4 binding could sta-
bilize unstable TTR tetramers in the ER, facilitating ex-
port and their secretion, we added T4 and other known
tetramer stabilizers to the cell medium of transiently
transfected BHK cells (Figure 6). In addition to T4 (Kd1 =
10 nM, Kd2 = 1 M), we examined the effects of the
small molecule stabilizers 1 (Kd1 = Kd2 = 5 nM [Hammar-
strom et al., 2003b]), and 2 (Green et al., 2003) on TTR
secretion (Figure 6A). Compound 2 is a bivalent small
molecule that simultaneously binds to both T bindingFigure 6. Metabolite Chaperoning of A25T, D18G, and Wild-Type TTR Secretion
(A) Structures of thyroxine (T4), 1, and 2.
(B) Quantification of the effect of T4 on A25T TTR secretion efficiency from BHK cells (defined in Figure 1). Vehicle (DMSO) only (filled squares);
0.1 M T4 (open squares); 1.0 M T4 (closed circles); 2.5 M T4 (open circles).
(C) Quantification of TTR secretion at 90 min (evaluated as in Figures 1C and 1F) with vehicle (DMSO), black bars; 2.5 M T4, white bars; 2.5
M 1, gray bars; and 2.5 M 2, hatched bars.
(D) Secretion efficiency (defined in Figure 1) of TTR from a choroidal epithelium cell line. Wild-type (open circles); L55P (filled circles); A25T
(filled squares); D18G (open triangles).4sites just prior to tetramer assembly and does not dis-
sociate from the tetramer without tetramer dissoci-
ation, hence its Kd is not measurable nor would it be
meaningful (Green et al., 2003). These stabilizers bind
more strongly to the native tetrameric state than to the
dissociative transition state, hence they make the ki-
netic barrier for tetramer dissociation (rate-limiting for
TTR amyloidosis) insurmountable, preventing amyloid-
ogenesis (Hammarstrom et al., 2003b). Addition of T4 to
the cell media of A25T-transfected BHK cells increased
A25T secretion efficiency in a dose-dependent fashion,
reaching maximal efficiency with the addition of 1 M
hormone (Figure 6B). Increases in both A25T and D18G
secretion were observed when BHK cells expressing
these variants were incubated with T4, 1, and 2 (2.5 M;
Figure 6C). Addition of T4, 1, and 2 (2.5 M) to BHK
cells expressing wild-type TTR had no effect on secre-
tion levels (Figure 6C). Addition of small molecules to
Cell
80the media had a greater effect on the total amount of d
mA25T secreted relative to D18G because A25T readily
forms a tetrameric structure, required for small mole- D
acule binding and stabilization (Figure 6C). Small mole-
cules do appear to tetramerize a small fraction of D18G t
aTTR by shifting the equilibrium away from the monomer
(Hammarstrom et al., 2003a), rationalizing the slight in- f
tcrease in secreted D18G (Figure 6C). Treating BHK cells
cotransfected with both D18G and FT2-wild-type TTR k
h(see Supplemental Discussion and Figure S2) with T4,
1, and 2 (2.5 M) demonstrated a much higher level of b
oD18G secretion, consistent with the increased stability
of D18G-containing heterotetramers rich in wild-type e
nsubunits found in heterozygotes (Figure 6C, far right).
t
FChoroid Plexus Cell Lines Secrete A25T TTR More
cEffectively Than BHK and MMH Cell Lines
oD18G and A25T heterozygotes exhibit symptomatic
sTTR deposition on the leptomeningeal membrane prox-
imal to the choroid plexus (Sekijima et al., 2003; Gar-
zuly, 1996; Garzuly et al., 1996; Hammarstrom et al., D
2003a; Harkany et al., 2002). This CNS pathology may
occur because of increased secretion efficiency of O
gA25T and D18G TTR by the choroid plexus into the CSF
relative to the low level of A25T and D18G secreted by m
athe liver into the blood (Hammarstrom et al., 2003a;
Sekijima et al., 2003). Such increased secretion could b
eresult from inherent cellular machinery differences, pos-
sibly mediated in full or in part by a T4 (metabolite) b
tchaperoning mechanism (Dickson et al., 1987; Miroy et
al., 1996). Choroid plexus cells are known to concen- l
wtrate T4 from the serum, providing a relatively high in-
tracellular concentration of a TTR ligand known to in- p
tcrease the secretion of destabilized TTR variants, an
effect that is amplified by the lack of other high affinity p
tT4 binders in these cells. Vaccinia transfection of rat
choroid plexus cells (Zheng and Zhao, 2002) reveals s
that A25T, but not D18G, is secreted from these cells
as efficiently as wild-type TTR (Figure 6D), demonstrat- A
ing an increase in the secretion aptitude of choroid S
plexus cells relative to BHK/MMH cells. Addition of T4 E
to the choroid plexus cells displayed a small but repro- W
ducible enhancement of the secretion levels of both b
A25T and wild-type TTR (Figure S3), suggesting that rat t
choroid plexus cells may be optimized for the use of T4 m
chaperoning to enhance export. D18G is not secreted b
from the choroid plexus cells (Figure 6D), indicating that s
this highly unstable variant is still too destabilized to be o
efficiently secreted. Rat TTR present at relatively low s
levels in the choroid epithelial cells (Zheng and Zhao, o
2002) could not be detected in mock transfections, t
hence it is unlikely that mixed tetramer formation is the f
basis for the enhanced secretion of A25T TTR. d
f
iThe Combined Stability Score Best
Predicts Amyloidogenicity t
pWhile the above studies focus on secretion efficiency
as a means of controlling the extracellular concentra- a
ttion of the amyloidogenic TTR variants, another con-
sideration is the inherent amyloidogenicity of the TTR t
itetramers once secreted. TTR will form amyloid fibrils
in vitro under denaturing conditions that either lower (
tthe pH or the dielectric constant of the aqueous me-ium, promoting tetramer dissociation and partial
onomer denaturation (Hammarstrom et al., 2002;
obson, 2003). Therefore, we evaluated the optimal pH
nd pH range for fibril formation as well as fibril forma-
ion kinetics in 50% methanol for each disease associ-
ted TTR variant (Figure 7A). The t50 of MeOH-induced
ibril formation did not correlate strongly with either
hermodynamic stability (Cm; R2 = 0.16; Figure 7B) or
inetic stability (t1/2 dissociation; R2 = 0.61; Figure 7C);
owever, it correlates very well with a combined sta-
ility score (R2 = 0.79; Figures S4 and 7D). Similarly, the
ptimal pH for fibril formation correlates less well with
ither thermodynamic (Cm; R2 = 0.33; Figure 7E) or ki-
etic stability (t1/2 dissociation; R2 = 0.35; Figure 7F)
han it does with a combined stability score (R2 = 0.67;
igures S5 and 7G). Thus, extracellular amyloidogeni-
ity of TTR variants can be predicted, under a variety
f conditions when both thermodynamic and kinetic
tability are considered together.
iscussion
ur results support the hypothesis that the global ener-
etics of the protein fold, but neither kinetics nor ther-
odynamics alone predict relative secretion efficiency
nd amyloidogenicity. Secretion efficiency differences
ased on the protein chaperone and metabolite chap-
rone content of the ER in different tissues and possi-
ly other factors are likely to strongly influence the
issue specificity, severity, and age of onset of extracel-
ular amyloid diseases. We suggest that ERAF path-
ays guided by protein energetics and the action of
rotein chaperones and metabolite chaperones dictate
he fraction of protein in the ERAF versus the ERAD
athways, offering a chemical and biological explana-
ion for the folding and secretory aptitude of each tis-
ue (Figure 8).
Combination of Thermodynamic and Kinetic
tability of the Tetramer Predicts Secretion
fficiency and Amyloidogenicity
hile it has become dogma that thermodynamic sta-
ility predicts the secretion efficiency of proteins and
hat self-assembly must precede the secretion of oligo-
eric proteins, the data on which these hypotheses are
ased are sparse and are not supported by the current
tudy of TTR and its variants. The folding and assembly
f the vast majority of TTR variants occurs within a few
econds, approximately 1000-fold faster than the rate
f cellular secretion (Figure S6). The rate at which the
etramer dissociates and the position of the tetramer-
olded monomer-unfolded monomer-linked equilibria
etermine the steady-state population of unfolded/mis-
olded and folded protein, dictating how much protein
s targeted for ERAD and how much protein is directed
oward ER export, respectively, at constant rates of
rotein synthesis, secretion, and degradation. This
nalysis assumes that the folded protein is competent
o engage the COPII export machinery, an interaction
hat appears to be rate limiting for secretion. These
deas explain why TTR variants of high kinetic stability
t1/2 > 2 hr) are secreted normally irrespective of their
hermodynamic stabilities, consistent with their inability
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81Figure 7. Relationship between TTR Energetics and Amyloidogenesis
(A) Relationship between disease phenotype, sequence, and amyloidogenesis in vitro. The x axis indicates the range (line) and optimum pH
(symbol) for fibril formation, whereas the y axis indicates half-time (t50) for fibril formation initiated by MeOH-induced denaturation (50% v/v).
Symbols are the same as in Figure 5.
(B) The time to reach 50% fibril formation (t50) in aqueous MeOH does not strongly correlate with thermodynamic stability (red line is a linear
fit with R2 = 0.16; Table S2) or (C) tetramer dissociation rate (red line is a linear fit with R2 = 0.61; Table S2). In (D), the correlation improves
when considered in terms of the combined stability score calculated from linear regression analysis of a three-dimensional fit (Figure S4) that
considers both the kinetic and thermodynamic stability parameters simultaneously (see Supplemental Discussion) (red line is a linear fit with
R2 = 0.79).
(E) A poor correlation exists between the optimal pH of fibril formation and thermodynamic stability (red line is a linear fit with R2 = 0.33;
Table S2) or when the kinetics of tetramer dissociation are considered alone (F) (red line represents a linear fit with R2 = 0.35; Table S2). In
(G), the combined stability score, calculated from a linear regression analysis (described in Supplemental Discussion) of the three-dimensional
plot displayed in Figure S5, better correlates with the optimal pH for fibril formation (red line is a linear fit with R2 = 0.67).to dissociate and engage the ERAD machinery on a
timescale consistent with ER export (e.g., Figures 5A
and 8). Similarly, variants of high thermodynamic sta-
bility (CmR 2) are secreted normally regardless of their
kinetic stabilities (e.g., Figure 5B) because the equilib-
rium between the natively folded state and the unfolded
states lies heavily toward the native tetramer, a stateunable to interact with the ERAD machinery. Stably
folded monomeric variants of TTR, incapable of form-
ing tetrameric structures, are secreted with near-wild-
type efficiency and display secretion efficiencies that
correlate best with their thermodynamic stabilities,
consistent with the fact that their kinetics of folding and
unfolding are fast relative to their secretion. Secretion
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sERAD, ERAF, and Extracellular Amyloidogenesis
TCompeting ERAD and ERAF pathways dictate the ability of a pro-
tein to engage the COPII export machinery. Failure of a sequence t
to achieve a minimum CSS under conditions found in the ER results a
in ERAD. Metabolite chaperoning can compliment a deficient se- c
quence through ERAF, populating the tetramer by shifting the efolded monomer to tetramer equilibrium. As the protein traverses
pthe exocytic and endocytic compartments for secretion, it en-
mcounters a new environment in which the stability of the native
state may result in clearance or, in the case of amyloidogenic pro- f
teins, aggregation late in the secretory pathway or outside the cell. o
Once secreted, the CSS dictates whether the tetramer will remain c
stable and functional or whether it will dissociate, misfold, and ag- mgregate to a form amyloid.
uEefficiency dictates the extracellular concentration of
TTR, an important factor in the amyloidogenesis rate L
Tequation; hence, the ability of the ER to export variant
protein appears to be an important parameter in dis- f
iease etiology.
Although the ER controls the concentration of the m
pamyloidogenic protein outside the cell, the proteins
proclivity to misfold is controlled by its inherent ener- f
tgetics. More specifically, amyloidogenicity correlates
best with a combination of kinetic and thermodynamic w
wstability reflected in the combined stability score. Tetra-
mer dissociation kinetics dictates the maximal rate of p
vamyloidogenesis, whereas thermodynamics prescribes
the concentration of TTR adopting an amyloidogenic c
pconformation, both being important factors in the amy-
loidogenesis rate equation. f
E
eERAD Generally Protects against Early
Onset Amyloidosis o
uThe vast majority of FAP variants, all less stable than
wild-type TTR, are secreted with near-wild-type-like C
pefficiency, and in these cases disease severity corre-ates with their combined stability score. The L55P vari-
nt has the lowest combined stability score that per-
its secretion at wild-type-like levels—rationalizing
his variant’s severe early onset FAP (w20 years of age).
or TTR sequences secreted at normal levels, the
lasma concentration (3–7 M) is as much as two or-
ers of magnitude higher than the CSF concentration
0.04–0.4 M), likely explaining why systemic disease
s more common than CNS amyloidosis. Ironically, vari-
nts more destabilized than L55P (Figure 5) lead to
ilder systemic (non-CNS) amyloidosis, likely because
ubstantially less of these variants are secreted into the
lood, demonstrating the important interplay between
xtracellular concentration and the combined stability
core. ERAD protects us from severe early onset sys-
emic amyloidosis in most tissues, a hypothesis sup-
orted by the fact that severe systemic pathology is
ot observed from the most destabilized TTR variants.
issue-Specific Secretion Differences Can
xplain Why D18G and A25T TTR Lead
o CNS-Selective Amyloidosis
lthough numerous amyloidoses display tissue-selec-
ive deposition and pathology, the mechanism remains
nclear. We demonstrated that the choroidal cell line
s more permissive in its ability to secrete the highly
estabilized A25T TTR variant and that A25T TTR
ecretion is sensitive to T4 (metabolite) chaperoning.
he secretory aptitude of the choroid cells increases
he extracellular concentration and rate of A25T TTR
myloidogenesis. The ability of choroid plexus cells to
oncentrate T4 (Dickson et al., 1987) from serum may
nable T4 to act transiently as a chemical chaperone,
otentially explaining deposition on the leptomeningeal
embrane proximal to the choroid plexus, resulting
rom T4 dissociation. We ascribe the late age of onset
f D18G and A25T TTR CNS pathology to the low con-
entration of these variants in the CSF. The extracellular
atrix and tissue-specific clearance may also contrib-
te to tissue-selective amyloidosis.
RAF Leads to Secretion Whereas ERAD
eads to Degradation
he combined stability score provides a quantitative
ramework to begin to assess the functions of the ER
n protein folding and export (Figure 8), the latter being
ediated by the COPII protein complex that recruits
roteins to budding vesicles for delivery to the cell sur-
ace (Lee et al., 2004; LaPointe et al., 2004). We find
hat the ER allows numerous pathologic TTR variants
ith reduced combined stability scores to be secreted
ith wild-type-like efficiency. This was surprising, as
revious studies on ER function have led to the current
iew that export from the ER is monitored by a “quality
ontrol” process—taken to mean that the ER only ex-
orts proteins that are stable relative to the wild-type
old. In contrast, we found that export is coupled to
RAF pathways. These pathways are influenced by the
nergetics (dynamics) of the protein fold and numerous
ther factors that define the relative affinity of the pop-
lation of partially folded or folded proteins for the
OPII machinery versus the population of unfolded
roteins destined for ERAD. The properties of ERAF
Secretion Efficiency Influences Amyloidosis
83pathways are likely to be specific to each tissue, owing
to the unique distributions of protein chaperones, me-
tabolite chaperones, osmolytes, folding catalysts, and
the like that link the energetics of the protein fold to
either protein export or ERAD—offering a chemical and
biological explanation for the tissue selectivity of pro-
tein secretion and amyloidogenesis.
Experimental Procedures
Cell Culture and Generation of Mutant Constructs
BHK cells were cultured in Dulbecco’s minimal essential medium
(Life Technologies, Inc.) supplemented with 100 U/ml penicillin-
streptomycin, 3% bovine growth serum (Hyclone). Met murine he-
patocytes D3 (MMH) cells were cultured in RPMI 1640 medium
(Invitrogen) supplemented with 4 mM glutamine, 100 U/ml penicil-
lin-streptomycin, 10% FCS, 30 ng/ml IGF II, 50 ng/ml EGF, and 0.2
U/ml insulin on plates treated with collagen type III, 40 ng/ml, in
glacial acetic acid (Spagnoli et al., 1998). Z310 choroidal epithelial
cells (Zheng and Zhao, 2002) were cultured in Dulbecco’s minimal
essential medium (Gibco) supplemented with 10% fetal bovine se-
rum (Gibco), 100 U/ml penicillin-streptomycin, 40 g/ml gentamicin
(Sigma), and 10 ng/ml mouse EGF (BD Biosciences). TTR expres-
sion constructs were generated from human TTR cDNA sequences.
All TTR sequences were introduced into the NdeI and BamHI sites
of the pET3c vector (Novagen, Madison, Wisconsin) for expression
from the T7 promoter (Studier et al., 1990). Variant TTRs were gen-
erated utilizing the Quick Change site-directed mutagenesis pro-
cedure from Stratagene (La Jolla, California) using wild-type TTR
DNA as the template.
Transfection and Pulse Chase Procedure
BHK cells, MMH cells, and Z310 choroidal epithelial cells were in-
fected with a vaccinia T7 RNA polymerase recombinant virus
(vTF7-3; Fuerst et al., 1986). In brief, all cells were infected with
virus for 30 min and then transfected with 1 g of pET3c plasmid
DNA encoding for the wild-type or mutated TTR, which had been
premixed in Lipofectamine with Plus Reagent (Invitrogen) (Effec-
tene [Qiagen] was utilized for transfection of the Z310 choroidal
epithelial cells) (Tisdale et al., 1992; Wang et al., 2004). Transfec-
tion/expression efficiencies are 60%–80%. In our cotransfection
experiments, all transfected cells are expressing both plasmids,
owing to the high ratio of DNA (Figure S2 and Supplemental Dis-
cussion). Six hours posttransfection, the medium was removed and
the cells incubated for 15 min in methionine-free minimal essential
medium (Life Technologies, Inc.), biosynthetically labeled for 10 min
with Easy Tag Express [35S]-label (ICN Biomedicals, Inc., Irvine,
California), then chased for 90 min in culture media. To quantify
transport, both the intracellular and extracellular (secreted) forms
of TTR were incubated overnight at 4°C with a specific antibody to
TTR. Immunoprecipitates were washed 4 times with 10 mM Tris-
HCl (pH 7.5), 0.1% Triton X, boiled, then centrifuged. Samples were
analyzed by SDS-PAGE on 12% gels according to the method of
Laemmli (Laemmli, 1970). The gel was dried, and quantitation of
the TTR was accomplished using a PhosphorImager (Molecular Dy-
namics, Sunnyvale, California).
Cells incubated with thyroxine and small molecules 1 and 2 were
treated identically to above with the exception that small molecules
were added to all steps following the transfection with Lipofectam-
ine Plus. Small molecules were prepared in a 2.5 mM solution in
DMSO and diluted into the transfection reagents.
Indirect Immunofluorescence Microscopy
BHK cells were grown on glass coverslips and transfected with 1
g of pCMV5 plasmid DNA encoding for the wild-type or D18G
TTR, which had been premixed in Lipofectamine with Plus Reagent
(Invitrogen). 16 hr post-transfection, cells were fixed in 3.7% form-
aldehyde/PBS, and then permeabilized with –20°C methanol. After
blocking with 3% BSA/TBS, BHK cells were incubated with rabbit
polyclonal antibodies against calnexin (StressGen) to localize the
ER, monoclonal antibody against α-1,2-mannosidase II (Covance
Research Products) to localize the Golgi apparatus, or goat poly-clonal antibodies to detect transfected TTR (EY Laboratories), and
then with fluorescein anti-rabbit conjugates (Jackson Immuno Re-
search), fluorescein anti-mouse conjugates (PIERCE) or rhodamine
anti-goat conjugates (Jackson Immuno Research).
Proteasome Inhibitor Treatment
BHK cells were transfected with 1 g of pCMV5 plasmid DNA en-
coding for the WT or D18G TTR, which had been premixed in Lipo-
fectamine with Plus Reagent (Invitrogen). Fifteen hours after trans-
fection, culture media was replaced with media containing
proteasome inhibitors. Thirty micromolar MG132 (Calbiochem), 10
M lactacystin (Calbiochem), 5 M epoxomicin (Calbiochem), or
DMSO alone was added to the culture media, and the cells were
cultured for 2 hr. Cells were then pulse labeled and chased for 6 hr
in the presence or absence of proteasome inhibitors.
Protein Expression and Purification
Recombinant wild-type TTR and variants were expressed in BL21/
DE3 Epicurian gold Escherichia coli (Stratagene) transformed with
the pmmHα plasmid containing the TTR and ampicillin resistance
genes. Expression and purification were performed as described
previously (Lashuel et al., 1999).
Urea-Mediated TTR Denaturation Measured
by Tryptophan Fluorescence
Samples containing TTR (0.1 mg/ml) were incubated (25°C) in vari-
ous concentrations of urea in 50 mM phosphate buffer (pH 7.0) (100
mM KCl, 1 mM EDTA, 1 mM DTT) for 96 hr. All TTR Trp fluorescence
spectra were recorded over the range of 310–410 nm using an ATF
105 Aviv spectrofluorometer equipped with a thermostated cell
holder employing excitation at 295 nm. Native wild-type TTR exhib-
its a fluorescence maximum at 337–338 nm, whereas the unfolded
protein shows maximum emission between 355 and 358 nm (Ham-
marstrom et al., 2002). Each subunit of TTR has two tryptophans
(residues 41 and 79). We used the 355 nm:335 nm emission inten-
sity ratio (F355/F335) to follow denaturation by the exposure of the
tryptophans as a function of chaotrope concentrations. The ratio
increased from 0.85 to 1.4 upon denaturation.
Rate of Tetramer Dissociation Detected by Linkage
to Monomer Unfolding Measured
by Tryptophan Fluorescence
The evaluation of tetramer dissociation rates was carried out using
TTR (0.1 mg/ml; 50 mM phosphate buffer, 100 mM KCl [pH 7], 25°C)
samples in 3.5–9 M urea, concentrations in the posttransition re-
gion for tertiary structural changes. The Trp fluorescence emission
ratio (F355/F335) as a function of time (25°C) was measured to
evaluate the tetramer dissociation rate by linking it to tertiary struc-
tural changes, as described in detail previously (Jiang et al., 2001;
Hammarstrom et al., 2002). The kinetic data fit well to a single ex-
ponential function: I355/335 = I355/335N + A(1 − e−kdiss t); where
I355/335N is the native protein fluorescence intensity ratio (355/335
nm), A is the amplitude difference, kdiss is the tetramer dissociation
rate constant and t is time in hr. The ln kdiss versus urea concentra-
tion plot is linear, allowing extrapolation to 0 M urea.
Supplemental Data
Supplemental Data include six figures and two tables and can be
found with this article online at http://www.cell.com/cgi/content/
full/121/1/73/DC1/.
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